The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma efficacy and safety of patients: A real-world study.
 
Yi Bai
No Relationships to Disclose
 
Jianfa Yu
No Relationships to Disclose
 
Chuanliang Cheng
No Relationships to Disclose
 
Dapeng Chen
No Relationships to Disclose
 
Yamin Zhang
No Relationships to Disclose